


Data Sheet

| | |
|--------------------|---|
| Product Name: | Exendin-4 |
| Cat. No.: | HY-13443 |
| CAS No.: | 141758-74-9 |
| Molecular Formula: | C184H282N50O60S |
| Molecular Weight: | 4186.57 |
| Target: | Glucagon Receptor |
| Pathway: | GPCR/G Protein |
| Solubility: | DMSO: \geq 32 mg/mL; H ₂ O: 1.23 mg/mL (Need ultrasonic and warming) |



BIOLOGICAL ACTIVITY:

Exendin-4, a 39 amino acid peptide, is a long-acting **glucagon-like** peptide-1 receptor agonist with an **IC₅₀** of 3.22 nM. IC₅₀ & Target: IC₅₀: 3.22 nM (glucagon-like peptide-1 receptor)^[1]

In Vitro: In human umbilical vein endothelial cells, exendin-4 significantly increases NO production, endothelial NO synthase (eNOS) phosphorylation, and GTP cyclohydrolase 1 (GTPCH1) level in a dose-dependent manner^[2]. Exendin-4 shows cytotoxic effects to MCF-7 breast cancer cells with IC₅₀ of 5 μ M at 48 hour^[3].

In Vivo: Both low- and high-dose exendin-4 treatment in *ob/ob* mice improve serum ALT and reduce serum glucose, insulin levels and calculated HOMA scores compared with control. Exendin-4-treated *ob/ob* mice sustain a marked reduction in the net weight gain in the final 4 weeks of the study period^[4]. Animals treated with exendin-4 have more pancreatic acinar inflammation, more pyknotic nuclei and weigh significantly less than control rats. Exendin-4 treatment is associated with lower insulin and leptin levels as well as lower HOMA values in rats^[5]. Exenatide causes dose-dependent relaxation of rat thoracic aorta, which is evoked via the GLP-1 receptor and is mediated mainly by H₂S but also by NO and CO^[6].

PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: ^[4]^[5]Rat: 20 Sprague-Dawley male rats, ten of which are treated with exendin-4 (10 μ g/kg) and ten of which are used as controls. The study period is 75 days. Serum and pancreatic tissue are removed for biochemical and histological study. Blood glucose, amylase, lipase, insulin and adipocytokines are compared between the two groups^[5].

Mouse: The exendin-4 treatment groups are treated with 10 μ g/kg every 24 hours for the first 14 days. This treatment is the induction phase. Respective control mice (lean and *ob/ob*) receive saline every 24 hours. After 14 days Exendin-4-treated mice are randomly divided into two groups: one group receives high dose exendin-4 (20 μ g/kg) every 12 hours, while the second group continues with low dose exendin-4 (10 μ g/kg) every 12 hours. The control mice continue to receive saline every 12 hours. The mice are weighed daily for the 60-day treatment period^[4].

References:

- [1]. Doyle ME, et al. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept. 2003 Jul 15;114(2-3):153-8.
- [2]. Wei R, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E947-57.
- [3]. Fidan-YaylalI G, et al. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol. 2016 Feb;37(2):2647-53.

- [4]. Ding X, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/obmice. *Hepatology*. 2006 Jan;43(1):173-81.
- [5]. Nachnani JS, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. *Diabetologia*. 2010 Jan;53(1):153-9.
- [6]. Selley E, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. *Cardiovasc Diabetol*. 2014 Apr 2;13:69.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA